Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
作者
João Paulo Camporez,Max C. Petersen,Abudukadier Abulizi,Gabriela Moreira,Michael J. Jurczak,Glenn C. Friedman,Christopher M. Haqq,Kitt Falk Petersen,Gerald I. Shulman
Sarcopenia, or skeletal muscle atrophy, is a debilitating comorbidity of many physiological and pathophysiological processes, including normal aging. There are no approved therapies for sarcopenia, but the antihypertrophic myokine myostatin is a potential therapeutic target. Here, we show that treatment of young and old mice with an anti-myostatin antibody (ATA 842) for 4 wk increased muscle mass and muscle strength in both groups. Furthermore, ATA 842 treatment also increased insulin-stimulated whole body glucose metabolism in old mice, which could be attributed to increased insulin-stimulated skeletal muscle glucose uptake as measured by a hyperinsulinemic-euglycemic clamp. Taken together, these studies provide support for pharmacological inhibition of myostatin as a potential therapeutic approach for age-related sarcopenia and metabolic disease.